FRANKFURT: CureVac is still in discussions with pharma majors to find a potential partner for its experimental COVID-19 vaccine, the German biotech firm’s chief executive said on Thursday.
“The location of the partner does not play a role. We are looking for a partner who is best placed to support us,” Chief Executive Franz-Werner Haas told a media briefing.
He said that a global infrastructure to monitor possible side effects after market launch was among the aspects to be addressed by a partner, but he added that CureVac may also outsource this task to a service provider.
Haas said the group was close to launching a Phase III trial with about 36,000 participants to find out whether its vaccine can prevent infections and that it plans to produce 300-400 million vaccine doses next year.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor
Read all the Latest News, Breaking News and Coronavirus News here
Comments
0 comment